After months of rumours and negotiations, the buy-out of Genzyme by pharma giant Sanofi-Aventis (SA) looks soon to become a reality. Internet sources report that SA may announce an agreement today.
We hope that the existing good partnership of IPA and industry will continue no matter what label is attached to the life-saving drugs for the therapy of rare diseases, namely for Pompe Disease.
Sources